MSB Trading - 2020, page-11087

"Big odds and a long long way to go"??
You do understand that Remestemcel is being reviewed by the FDA under Priority-Review and Fast-Track status (incredible confidence by the FDA to give them these designations), with a decision by September at the latest. That's 4 months away, after over a decade of trials that have proven their treatment has a great safety profile and is effective at increasing the survival rates of very sick children. That same treatment is also now only months away from completing a trial that will determine the fate of adults who are otherwise given a 12% chance of survival from Covid-induced ARDS.

4 months in a biotech pipeline is a very very short way to go.

It's a sunny day in Melbourne, your wet blanket attitude should be hung on the line to dry